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In proton therapy, high-energy proton beams cause the production of secondary neu-
trons. This leads to an unwanted dose contribution, which can be considerable for tissues
outside of the target volume regarding the long-term health of cancer patients. Due
to the high biological effectiveness of neutrons with regard to cancer induction, small
neutron doses can be important. Published comparisons of neutron dose measurements
and the corresponding estimates of cancer risk between different treatment modalities
differ over orders of magnitude. In this report, the controversy about the impact of the
neutron dose in proton therapy is critically discussed and viewed in the light of new
epidemiological studies. In summary, the impact of neutron dose on cancer risk can be
determined correctly only if the dose distributions are carefully measured or computed.
It is important to include not only the neutron component into comparisons but also
the complete deposition of energy as precisely as possible. Cancer risk comparisons
between different radiation qualities, treatment machines, and techniques have to be
performed under similar conditions. It seems that in the past, the uncertainty in the models
which lead from dose to risk were overestimated when compared with erroneous dose
comparisons. Current risk models used with carefully obtained dose distributions predict
a second cancer risk reduction for active protons vs. photons and a more or less constant
risk of passive protons vs. photons. Those findings are in general agreement with newly
obtained epidemiologically results.
Keywords: proton therapy, neutrons, second cancer
INTRODUCTION
During proton therapy, neutrons are produced. This is known since protons are used for applications
in radiation therapy. It is also known that the neutron absorbed dose is small. However, neutrons
are highly biological effective and thus even a small absorbed dose might cause side effects in the
patient, the most severe of which is the induction of a second primary cancer. For this reason, since
the 1990s, the following main approaches to quantify the neutron absorbed and equivalent dose in
radiotherapy patients include:
(i) Neutron, proton, and photonuclear cross-sections and neutron kerma coefficients for radiation
therapy were determined based on experimental data and nuclear model calculations. Such data
permit calculations of absorbed dose in the body from therapy beams, and through use of kerma
coefficients allow absorbed dose to be estimated for a given neutron energy distribution. Most
work in the beginning was done by Chadwick (1) and was extended afterward by many other
authors.
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(ii) Monte Carlo simulations of the neutron dose and neutron
energy spectra were performed for typical proton therapy
facilities. First work was published by Agosteo et al. (2)
and Siebers (3) and further work was published since then,
including very detailed simulations of proton therapy beam
lines including realistic patient geometries.
(iii) Measurements and calculations of the quality factor of neu-
tronswith the endpoint of cancer induction (and/or chromo-
somal aberrations, clonogenic survival, neoplastic transfor-
mations, etc.) were performed.Many studies were conducted
starting in the 1970s. Much work was motivated by space
radiation research and the A-bomb survivor analysis [e.g.,
Ref. (4–6)]. Later, also nanodosimetric measurements were
used to characterize the quality factor of neutrons produced
by proton beams (7).
(iv) Measurements of neutron absorbed dose and neutron dose
equivalent at proton therapy beam lines were executed. First,
measurements on passive beam lines were undertaken by
Binns and Hough (8) and Yan et al. (9) and for active beam
lines by Schneider et al. (10). Since then, a large number of
neutron dose measurements were reported including several
beam lines, in patient measurements, as well as measure-
ments in treatment rooms, including a variety of dosime-
ters and set-ups including neutron energy spectra measure-
ments. In addition, analytical methods were developed to
determine neutron dose equivalent (11).
The resulting measured or simulated neutron dose distribu-
tions were used to estimate the risk for radiotherapy patients
to develop secondary malignancies. Two strategies were usually
applied. Either the neutron dose distribution was viewed as an
additional dose burden to the patient, independently of the deliv-
ered dose to treat the tumor. As the neutron doses are usually
low, radiation protection models were used to convert dose to
risk. Another possibility is to combine the neutron dose with the
dose distribution delivered by the therapy protons. The resulting
dose levels are then much larger than the scope of radiation
protectionmodels and thus newly developedRT-risk-modelswere
used to study the impact of the additional neutron dose. The
latter models include, therefore, also the impact of integral dose
changes on cancer risk. In the year 2006, two reports (12, 13), using
these concepts, were published. The two strategies which were
used to estimate second cancer risk came to completely contrary
conclusions. Hall (12) estimated the risk of second malignancies
by analyzing the stray and neutron doses alone and concluded
that passive proton therapy would result in up to 20 times more
second cancers than conventional photon radiotherapy. On the
other hand, Schneider et al. (13, 14) determined cancer risk by
analyzing the complete dose distribution including the energy
deposited by primary protons and neutrons. They found for active
proton therapy a decrease in second cancer risk. For passive
proton therapy, by scaling the neutron dose, the risk was more
or less the same when compared to conventional photons. This
resulted in a heavily discussed controversy about the future of
proton therapy.
In this report, we highlight the controversy about the impact of
the neutron dose in proton therapy, which is critically discussed
and viewed in the light of new epidemiological studies. The aim
of this work is not to provide a review summarizing the cur-
rent knowledge of neutron dose measurements, calculations or
simulations, and the resulting cancer risk estimates.
MEASURED AND SIMULATED
NEUTRON DOSE
It is of importance that dose and risk comparisons with regard
to radiation quality and treatment technique are performed using
the same phantom or patient, the same experimental equipment
and is based on the same clinical indication. Treatment planning
should be performed using the same dose constraints for target
and normal tissues. If measurements of different experimental
set-ups are compared very easily, apples and oranges are com-
pared. Figure 1A shows a dose comparison from Ref. (12), where
measurements obtained by different researchers were compared.
On the basis of Figure 1A, Hall (12) has drawn the conclusion
that IMRT with photons would double the incidence of solid
cancers in long-term survivors and passive proton therapy would
result in up to 20 times more second malignancies. The dose scal-
ing of the different experimental results, which led to Figure 1A,
were highly questioned and resulted in the exchange of several
letters to the editor.
A fair comparison of stray doses is shown in Figure 1B, which
was obtained using for the investigated treatment modalities and
techniques the same phantom and the same treatment indication
(15). For the measurements at the passive proton therapy, beam
line compensators were used which were produced specifically
for this case. As a result, the distribution of the neutron dose of
scattered protons is completely different when compared to the
published data of Hall (12) reaching two orders of magnitude at
40 cm distance from the field edge. Clearly, the conclusion drawn
by Hall was wrong, as he used erroneous stray dose estimates.
Using the dose results of Figure 1B, one would expect for passive
proton therapy approximately the same amount of neutron dose
than photon stray dose produced by conventional 3D conformal
radiotherapy. However, it should be noted here that the neutron
measurements are related to large errors and that the quality factor
for cancer induction is not well known. In addition, the effect of
prompt gamma radiation in proton therapy was not considered.
MODELS OF SECOND CANCER
INDUCTION
Estimates Based on Dose Comparison
Using simple dose comparisons for risk estimates by applying data,
as shown in Figure 1, can be unsafe for two reasons. The decrease
of dose as a function from field edge is exponential or sometimes
even more than exponential. Since risk is both a function of dose
and irradiated volume, it is very important to analyze carefully
the shape of the dose curves close to the target volume. For
example, when using IMRT techniques with photons, the dose
far away from the field edge might by larger when compared to
3DCRT. However, the dose close to the field edge is lower for
IMRT techniques. The reason for this is that IMRT produces less
phantom scatter, which is themajor stray dose component close to
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FIGURE 1 | (A) Eric Hall’s comparison (12) of neutron dose equivalent per treatment Gray as a function from the distance of the field edge. Measurements of several
researchers were combined by scaling the neutron dose. (B) Comparison of neutron dose equivalent by Hälg et al. (13). The measurements were performed under
the same conditions for each treatment modality.
the target. Although the affected volume might be small, the dose
at around 10 cm from the field edge can bemore than amagnitude
larger than far away from the treatment field.
The second reason is that we do not get an idea about the full
3D-dose distribution by analyzing only certain components of
the dose, e.g., the neutron dose. Generally the dose distribution
can be separated into two parts. The in-field dose is created by
particles impinging on the patient through the opening of the
beam aperture. This includes in-field scattering mainly produced
by Compton scattering (photons) and multiple Coulomb scat-
tering or inelastic nuclear interactions (protons and ions). The
out-of-field dose is generated by phantom scatter and radiation
scattered by the treatment head, leakage radiation through the
collimators and neutrons, and prompt gammas produced either
in the machine or the patient.
For a reliable risk estimate of the patient, it is required to study
the deposited energy of all components. In doing so, the char-
acteristics of dose deposition of the different radiation qualities
are taken into account. If, for example, photons are compared
to protons, the integral dose in the highly irradiated volumes is
always a factor of 2–3 lower for protons, independently of the
treatment technique (16). That must have an impact on cancer
induction and cannot be neglected.
In summary, relative risk estimates using comparisons of dose
distributions are possible. However, it is essential that the correct
dose distributions are compared, including all relevant stray dose
components. The comparisons must be obtained by selecting
carefully the same conditions for all treatment types in questions
if dose measurements or simulations are performed. Currently,
measurements as well as analytical or Monte Carlo simulations
can predict stray doses with a precision of around 20–50%.
Estimates Based on Risk Models
Simple models to predict risk of radiation-induced cancer for
radiotherapy dose levels are based on conventional concepts from
radiation protection, i.e., ICRP (17) or BEIR (18). These models
are based on the linear approximation of the risks of the Atomic-
bomb survivors and use effective dose (the tissue-weighted sum
of the equivalent doses in all specified tissues) for risk estimation.
Basic risk factors are usually modified by a dose and dose-rate
effectiveness factor (DDREF) for the application to low dose-rates.
The linear model is only valid for doses up to around 1–2Gy and
as such, is in general, not applicable to complete radiotherapy dose
distribution.
Radiation protectionmodels can be safely applied exclusively to
the dose originating from scatter radiation. In principle, the linear
model is applied to very low doses with a threshold of around
100mSv. The threshold represents the maximum applied scatter
dose during a typical radiotherapy treatment (Figure 1B, if scaled
to a typical RT dose). As for such estimates, only the out-of-field-
dose is considered, but the in-field dose distribution completely
neglected, cancer risk is not a function of the integral dose, but
proportional to the amount of scatter dose. As a consequence,
such studies result in an estimated increase of cancer risk of
modern radiotherapy techniques (12). The reason for this is the
larger amount of scatter, leakage, and neutron dose of those treat-
ment modalities compared to conventional treatment techniques.
While in such situations the application of radiation protection
concepts may be appropriate, since exclusively the low doses are
investigated, the main disadvantage of such an approach is that
the in-field dose distribution (>100mSv) is completely neglected.
Thus, risk estimates based on scatter dose would only include
second cancer induction far away from the treated side. It is
reported, however, that only around 20% of all radiation-induced
malignancies are found far away from the treated volume (19).
In summary, radiation protection models should be used only
with extreme care for risk estimates in radiotherapy since they
are developed exclusively for low dose. When applied to scatter
radiation, such models can predict only a fraction of observed
second malignancies.
It is also possible to take for cancer risk estimates the complete
3D-dose distribution (in- and out-of-field) into account by using
semi-empirical models of cancer induction. Such models include
the effect of dose fractionation and represent the dose–response
relationships more accurately. The involved uncertainties are still
huge for most of the organs and tissues. A major reason for this
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FIGURE 2 |Modeled second cancer risk after radiotherapy of the prostate relative to a historic radiation treatment (four-field-box in blue). The data
were taken from Ref. (14) and updated with better dose measurements (15). Prostate cancer was chosen for comparison with the epidemiological study of Chung
et al. (21) as their patient cohort consisted mainly of prostate patients.
is that the underlying processes of the induction of carcinoma
and sarcoma are not well known. Most uncertainties are related
to the time patterns of cancer induction, the population specific
dependencies and to the organ-specific cancer induction rates.
For radiotherapy treatment plan optimization, these factors are
irrelevant as a treatment plan comparison is performed for a
patient of specific age, sex, etc. If a treatment plan is compared
relative to another, a precision of around 10% can be achieved (20).
Such a model was used in Ref. (13) for cancer risk estimates after
prostate radiotherapy by using the complete 3D-dose distribution
including stray dose estimates. It was found that the additional
dose of neutrons during proton radiotherapy is balanced by the
integral dose advantage of proton beams. The predicted risk of
passively scattered protons is, thus, slightly lower than of photon
3DCRT. Actively applied proton beams resulted inmore than 50%
reduced risk prediction relative to 3DCRT (Figure 2).
QUALITATIVE COMPARISON OF MODEL
PREDICTIONS WITH EPIDEMIOLOGICAL
FINDINGS
In 2006, when contradicting model results were published (12,
13), no epidemiological study regarding second cancers after pro-
ton therapy or IMRT was available. The users of proton therapy
machines, and also the clinicians who were using photon IMRT,
were confused about which models to believe. On the one hand,
Eric Hall (12) predicted, by using stray dose comparisons, a 2- and
20-time larger second cancer risk for IMRT and passive proton
therapy, respectively. On the other hand, risk models that were
applied to the complete dose distribution of a patient predicted
more or less the same risk for IMRT using 6MV photons and
passive proton therapy (13, 14).
In 2013, the first epidemiological study on a comparison of
second cancer risk between a photon and proton-treated group
was published by Chung et al. (21). They found that the use of
proton radiation therapy using passively scattered protons was not
associated with a significantly increased risk of secondary malig-
nancies compared with photon therapy. Although they state, that
longer follow-up of these patients is needed to determine if there
is a significant decrease in second malignancies, they found an
adjusted hazard ratio of 0.52 [95% confidence interval, 0.32–0.85]
of protons vs. photons. These first epidemiological results strongly
suggest that the exaggerated risk estimates of Ref. (12) which were
based on a faulty stray dose comparison were wrong.
In a study published 2014, Sethi et al. (22) examined in-field and
out-of-field cancer incidence in proton vs. photon-treated patients
with retinoblastoma. In-field cancer was significantly higher in
photon-treated patients. With an ~7-year median follow-up, the
incidence of out-of-field cancer did not significantly differ in the
proton- vs. photon-treated patients. These results are in accor-
dance with the integral dose advantage of protons vs. photons and
the comparable stray doses for scattered protons and 3DCRT, as
shown in Figure 1B.
CONCLUSION
Most criticisms of cancer risk estimates are usually given to the
uncertainties of risk models, which lead from dose to second
cancer risk. We are concerned that there is too little thought being
given to the very simple ideas on which cancer risk models are
based upon and too little objections about accepting the impli-
cations of such models. However, even more important are the
errors and uncertainties in the dose distributions, which are the
basis of risk modeling. If the dose is wrongly quantified, like in
Figure 1A, this leads inevitably to wrong risk estimates, regardless
of the quality of the used risk models. It is also important to
always take the full dose distribution into account and not only
parts of it. This is of particular importance when photon therapy
is compared to proton therapy, as the integral dose advantage
of proton therapy in the highly irradiated volumes can be bal-
anced by the neutron dose in the areas distant from the irra-
diation fields. Unfortunately, researchers are often using over-
simplified dose estimates, by applying risk models e.g., to dose
distributions obtained from radiotherapy treatment planning
systems.
In summary, if carefully obtained dose distributions are used
with appropriate risk models to predict second cancer for radio-
therapy patients, a reduction for active and passive proton therapy
is predicted when compared to photons. Those findings are in
general agreement with newly obtained epidemiologically results.
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The estimates performed byHall (12) resulting in an order ofmag-
nitude enhanced risk of passive proton therapy are contradicted
by the findings of the epidemiological studies and various risk
estimates for radiotherapy patients.
In the future, it is important to gain more knowledge on the
RBE of neutrons with regard to cancer induction. It is necessary
to study RBE for tumor induction as a function of neutron dose,
energy, dose-rate, tissue type, and size of the exposed patient. Cur-
rently, the EU project ANDANTE (23) is exploring the question
of neutron RBE.
More research is also necessary to improve the precision of out-
of-field neutron dose calculations including the energy spectra.
This could make whole-body dose calculations available for risk
estimates of individual radiotherapy patients.
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